Emerging Therapies in IBD 2006
|
|
- Vivian Barker
- 5 years ago
- Views:
Transcription
1 Overview Emerging Therapies in IBD 26 David T. Rubin, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center University of Chicago Describe the unmet needs of therapy in IBD Emerging biologic therapy in IBD Adalimumab Natalizumab Discussion of potential strategies for the future New aminosalicylate formulation for UC: MMX Early phase development of other agents Why do we need new therapies in IBD? Substantial unmet needs Primary non-responders to standard therapies Unproven ability to change long-term outcomes Loss of response/intolerance due to immunogenicity or disease modification Dirty drugs We don t know how to predict response Systemic therapies probably not needed for local disease Emerging concerns about safety of existing therapies Infections Malignancies Cost! Surgery isn t what we d like it to be Recurrence rate in CD Pouch outcomes in UC What Pathways Are Important in IBD? Secretion of cytokines and other products from activated immune cells injury to the colon Activation of lymphocytes results in increased immune response Failure to downregulate Trafficking to the intestine of inflammatory leukocyte populations Judge et al. Inflammatory Bowel Disease. In Friedman et al, eds. Current Diagnosis & Treatment in Gastroenterology. 23;18. 1
2 Therapeutic Targets for IBD Antigens Activated macrophages IL-18 IL-12 Repair & Restitution Bacteria -Heparin -IL-11 -Nicotine Sargramostim (GM-CSF) Ag processing & presentation, Activation of macrophages: Inflammation and injury -Aminosalicylates -Sargramostim (GM-CSF) -Corticosteroids Ag recognition & activation of CD4+T Cells: Activated neutrophils IL-2 -AZA/6MP -CyA, Tacrolimus -Sargramostim (GM-CSF) -MTX, Cyclophosphamide IL-4 Second messenger systems: -MAPK inhibitors Crohn s Disease TNFα IFNγ ICAM-1 -Fontolizumab Generation of Th1/Th2 response: -Infliximab -IL-1 -IL-12, IL-18 IL-1 Recruitment, migration and adhesion: -Antisense, oligonucleotides to ICAM-1 -Anti-α4 integrin antibody Sands B. Gastroenterology 2;118:S68-S82. Key Actions Attributed to TNF Construct of the Anti-TNF Biologic Agents Macrophages Proinflammatory cytokines Chemokines Increased inflammation Cκ VL VH CH1 Endothelium Adhesion molecules Increased cell infiltration TNF Fibroblasts Epithelium Acute phase response Metalloproteinase synthesis Collagen production Ion transport Permeability Increased CRP in serum Tissue remodeling Compromised barrier function Infliximab Chimeric 75% human IgG 1 isotype PEG PEG pegol Pegylated Humanized 95% human Adalimumab Human 1% human IgG 1 isotype 2
3 Anti-TNF Biologic Agents Indications, Route of Administration, and Dosing Infliximab (infusion) Indicated for reducing the signs & symptoms and inducing & maintaining remission in adult & pediatric patients with CD and an inadequate response to conventional therapy Indicated for reducing the number of fistulas and for maintaining fistual closure in adults with CD dose: 5 mg/kg IV at, 2, and 6 weeks dose: 5 mg/kg IV q 8 weeks Adalimumab (subcutaneous, pre-filled syringe, injectable pen) In development; has demonstrated significant efficacy in phase III studies in CD Loading dose: 16 mg at week ; 8 mg at week 2 dose: mg SC weekly vs mg SC every other week pegol (subcutaneous) In development; has demonstrated significant efficacy in phase III studies in CD Loading dose: mg SC at weeks, 2, 4 dose: mg SC q 4 weeks Clinical Trials with TNF Antagonists in Crohn s Disease Agent Infliximab Adalimumab F = fistulas; P = pediatric. Study Name ACCENT I ACCENT II REACH CLASSIC I CLASSIC II CHARM GAIN PRECiSE 1 PRECiSE 2 Reference Targan et al. N Engl J Med 1997 Present et al. N Engl J Med 1999 Rutgeerts et al. Gastroenterology 1999 Hanauer et al. Lancet 22 Aim of Study (F) Sands et al. N Engl J Med 24 Lichtenstein et al. Gastroenterology 25 (F) Hyams et al. DDW 26 & (P) Hanauer et al. Gastroenterology 26 Sandborn et al. UEGW 25 Colombel et al. DDW 26 Sandborn et al. ACG 26 2 o Infx failures Schreiber et al. Gastroenterology 25 Sandborn et al. DDW 26 & Schreiber et al. UEGW 25 CLASSIC I: Therapy With Adalimumab N = 299 anti-tnf naive Wk (n = 74) Hanauer S, et al. Gastroenterology. 26;13: Wk 2 Adalimumab mg wk 2 mg wk 2 (n = 74) Adalimumab 8 mg wk mg wk 2 (n = 75) Adalimumab 16 mg wk 8 mg wk 2 (n = 76) Wk 4 Remission (CDAI < 15) CLASSIC I: Results at Week 4 18 Adalimumab /2 Adalimumab 8/ Adalimumab 16/8 24 Clinical Remission Clinical Response Δ7 p <.5 vs placebo; p =.1 vs placebo; p =.7 vs placebo. Clinical remission = CDAI < 15; Clinical response = Δ7 or Δ1 is a 7 or 1 point decrease in CDAI from baseline. Hanauer S, et al. Gastroenterology. 26;13: Clinical Response Δ1 3
4 CHARM: of Clinical Response in Crohn s Disease With Adalimumab N = 854 Included patients with prior exposure to anti-tnf agents Wk Wk 2 8 mg mg Wk (58%) responders randomized EOW = every other week. Colombel JF, et al. DDW 26, Abstract 686d. Wk 26 (n = 17) mg EOW (n = 172) mg weekly (n = 157) Remission (CDAI < 15) Wk 56 Remission (CDAI < 15) CHARM: Clinical Remission at Weeks 26 and 56 With Adalimumab Randomized Responders (n = 499) Adalimumab mg EOW Adalimumab mg Weekly /17 68/172 73/157 2/17 62/172 65/157 N = Week 26 Week 56 p <.1 vs placebo. EOW = every other week. No statistically significant difference between mg EOW and mg weekly groups. Colombel JF, et al. DDW 26, Abstract 686d. 12 CHARM: Clinical Remission of CD Over Time With Adalimumab Randomized Responders (n = 499) Adalimumab mg EOW Adalimumab mg weekly p <.1 vs placebo; p =.5 vs placebo. EOW = every other week; remission = CDAI < 15. Colombel JF, et al. DDW 26, Abstract 686d. Weeks CHARM: Additional results Response (CR7) Week 26 Week 56 Steroid-free remission Weeks 26 Weeks 56 Remission (prior anti-tnf use) Weeks 26 Weeks 56 Remission (no prior anti-tnf use) Weeks 26 Weeks 56 Fistula healing Week 26 Weeks 26 and 56 # # includes all treated patients, randomized responders and randomized non-responders p<.1; p=.8; ^^p<.5; ^p<.1 vs placebo p=.43 both ADA groups combined vs placebo Colombel JF, et al. DDW 26, Abstract 686d ADA mg QOW ^^ 31^ ADA mg QW
5 CHARM: Serious Adverse Events All Patients Incidence of Anti-Adalimumab Antibodies (AAA) Adverse Event Infections (n[%]) Abscess Tuberculosis Other opportunistic infections Wound infection/ septicemia Pneumonia, chest infection Cancer (n[%]) Multiple sclerosis (n[%]) Serum sickness (n[%]) Death (n[%]) 4-Week OL (n = 854) 11 (1.3) 5 (.6) 3 (.4) 1 (.1) 1 (.1) 1 (.1) a (n = 261) 9 (3.4) 3 (1.1) 1 (.4) 1 (.4) 1 (.4) Post Randomization (Weeks 4 56) mg EOW (n = 535) 19 (3.6) 3 (.6) 1 (.2) 1 (.2) 1 (.2) 1 (.2) mg Weekly (n = 41) 11 (2.7) 4 (1.) 1 (.2) 2 (.5) RA Clinical Trials 1 Overall, approximately 5% of patients receiving adalimumab developed low-titer AAA at least once during treatment There was no apparent correlation between the development of AAA and the occurrence of adverse events CD Clinical Trials 2,3 CLASSIC I: 2 patients (.7%) positive for AAA (1 in the placebo group) CLASSIC II: 7 patients (2.6%) positive for AAA (1 in the placebo group) a Pulmonary embolus. EOW = every other week; OL = open label. Colombel JF, et al. DDW 26, Abstract 686d. 1. Data on file, Abbott Laboratories; 2. Hanauer SB, et al. Gastroenterology. 26;13: ; 3. Peng JZ, et al. DDW 26, Abstract T1133. PRECiSE 1: Safety and Efficacy of Pegol in Patients With Moderately to Severely Active CD N = 659 Included patients with prior exposure to anti-tnf agents Wk Sandborn WJ, et al. DDW 26. Abstract 745. Wk 2 Wk 4 Wk 6 Wk 26 Response q 4 wks ( n = 328 ) Stratified for CRP (< 1 mg/l vs 1 mg/l) Stratified for baseline steroids and immunosuppressants Response: Improvement in CDAI score 1 points Co-primary endpoints were assessed in patients with CRP 1 mg/l pegol mg q 4 wks (n = 331 ) Response (Weeks 6 & 26) PRECiSE 1: Clinical Response (CDAI 1) and Remission (CDAI < 15) Intent-to-Treat Population Clinical Response Clinical Remission p <.5 vs placebo; p <.1 vs placebo. Sandborn WJ, et al. DDW 26, Abstract Week 4 Week 6 Weeks 6 & Week 4 Week 6 Weeks 6 & 26 (n = 328) pegol mg (n = 331) 5
6 N = 668 Included patients with prior exposure to anti-tnf agents PRECiSE 2: of Remission in CD With Pegol Wk Wk 2 Wk 4 certolizumab pegol mg Wk 6 Wk (64.1%) responders randomized q 4 wks (n = 212) pegol mg q 4 wks (n = 216) Response (reduction in CDAI of 1 pts) PRECiSE 2: Clinical Response and Remission at Week 26 in Patients With CD Randomized Responders (N = 428) Clinical Response (decrease in CDAI 1 points) 63 q 4 wk (N = 212) pegol mg q 4 wk (N = 216) Clinical Remission (CDAI < 15 points) Schreiber S, et al. Gut. 25;54(Suppl VII):A82. p <.1 vs placebo. Schreiber S, et al. Gut. 25;54(Suppl VII):A82. PRECiSE 1 & 2: Safety and Tolerability of Pegol in CD PRECiSE 1 PRECiSE 2 Adverse Event (n[%]) (n = 329) (n = 331) (n = 668) (n = 212) (n = 216) Headache 54 (16.4) 6 (18.1) 84 (12.6) 14 (6.6) 15 (6.9) Abdominal pain 37 (11.2) 37 (11.2) 27 (4.) 1 (4.7) 1 (4.6) Crohn s disease 37 (11.2) 33 (1.) 36 (5.4) 25 (11.8) 9 (4.2) Nasopharyngitis 27 (8.2) 44 (13.3) 25 (3.7) 8 (3.8) 12 (5.6) Cough 8 (2.4) 9 (2.7) 5 (.7) 2 (.9) 12 (5.6) Nausea 27 (8.2) 26 (7.9) 24 (3.63) 6 (2.8) 6 (2.8) UTI 17 (5.2) 25 (7.6) 27 (4.) 5 (2.4) 8 (3.7) Pyrexia 22 (6.7) 21 (6.3) 16 (2.4) 7 (3.3) 1 (4.6) Arthralgia 16 (4.9) 22 (6.6) 16 (2.4) 6 (2.8) 1 (4.6) Injection site pain 23 (7.) 4 (1.2) 8 (1.2) 11 (5.2) 1 (.5) Back pain 17 (5.2) 9 (2.7) 11 (1.6) 9 (4.2) 1 (.5) Vomiting 11 (3.3) 18 (5.4) 14 (2.1) 3 (1.4) 1 (.5) PRECiSE 1 malignancies reported in 4 patients: 1 cervical cancer and 1 Hodgkin s lymphoma in the placebo group, 1 lung cancer and 1 rectal cancer in the certolizumab group. PRECiSE 2 no study-related malignancies were reported. Schreiber S, et al. DDW 26, Abstract T1126. Incidence of Antibodies to Pegol in Patients With CD 12.3% (9 of 73) of patients receiving certolizumab pegol mg had a least 1 positive result for anticertolizumab antibodies The plasma concentrations of certolizumab pegol were lower in the antibody-positive patients The proportions of patients who responded to treatment by week 12 were similar between antibody-positive and antibody-negative patients Schreiber S, et al. Gastroenterology. 25;129:
7 Construct and Mechanism of Action of Natalizumab Complementarity-Determining Regions (CDRs) Human IgG 4 Framework Natalizumab Humanized mab against α4-integrins Human IgG 4 framework with CDRs grafted from murine antibodies Mechanism of Action Binds to the α4 subunit of α4β1 and α4β7 integrins expressed on all leukocytes except neutrophils Prevents the interaction of leukocytes with vascular endothelial cells Inhibits transmigration of leukocytes across the endothelium into inflamed parenchymal tissue ENACT-1: Natalizumab for of Clinical Response in Patients With Moderately to Severely Active CD N = 95 Included patients with prior exposure to anti-tnf agents Wk ( n = 181) Stratified for CRP ( or > 2.87 mg/l) Concomitant immunosuppressants Prior use of anti-tnf agents Sandborn WJ, et al. N Engl J Med. 25;353: Wk 4 Wk 8 Wk 1 Wk 12 Natalizumab 3 mg (n = 724) Response (reduction in CDAI of 7 pts) ENACT-2: of Clinical Response With Natalizumab Response or Remission at Weeks 36 and Wk 36 Wk 6 Wk 36 Wk 6 Response Remission p <.5 vs placebo; p =.3 vs placebo; p <.1 vs placebo. Sandborn WJ, et al. N Engl J Med. 25;353: Withdrawal of Oral Corticosteroids During Sustained Remission Natalizumab 8 6 Natalizumab (n = 67) (n = 76) Weeks ENCORE: and of Response With Natalizumab in Patients With CD N = 59 Included only patients with elevated levels of CRP (> 2.87 mg/l) Wk Targan SR, et al. DDW 26, Abstract 747. ( n = 181) Wk 4 Wk 8 Wk 12 Natalizumab 3 mg (n = 724) Sustained Response at Weeks 8 & 12 (reduction in CDAI of 7 pts) 7
8 ENCORE: Clinical Response and Remission of CD in Patients Receiving Natalizumab p <.1 vs placebo; p <.2 vs placebo. Targan SR, et al. DDW 26, Abstract 747. Response ( 7) Remission (CDAI < 15) Wk 8 Wk 12 Wks Wk 8 Wk 12 Wks Natalizumab (n = 259) (n = 25) Natalizumab: Safety Most common AEs ( 1% of patients) were headache, nausea, and nasopharyngitis 8 14% of patients discontinued treatment due to AEs 3 cases of progressive multifocal leukoencephalopathy (PML) have been reported Patients in all clinical trials have been re-evaluated for PML 2,3 89% of eligible clinical trial patients participated (N = 3389) No additional, confirmed cases of PML were identified in > 3 patients PML was excluded in all but 1 patient, where repeat MRI and CSF were not available Estimated risk of PML in this population: 1 per 1 patients (.1%; 95% CI: per 1) 3 Incidence in CD: 1 in 1275 Incidence in MS: 2 in Sandborn WJ, et al. N Engl J Med. 25;353: ; 2. Sandborn WJ, et al. DDW 26, Abstract 492; 3. Yousry T A, et al. N Engl J Med. 26; 354: Natalizumab: Immunogenicity 8 9% of patients in ENACT-1 and ENACT-2 developed anti-natalizumab antibodies 1 therapy with natalizumab does not require concomitant administration of immunosuppressants for sustained efficacy in CD 2 Unanswered Questions About Biologic Therapy in IBD Do biologics change long-term outcomes in IBD? Where should biologic therapy fit in our treatment algorithm? Top down approach? Are concommitant immunosuppressives beneficial indefinitely or just early? Will Immunosuppressive therapy need to be used with newer biologic therapies? 1. Sandborn WJ, et al. N Engl J Med. 25;353: ; 2. Sandborn WJ, et al. DDW 26, Abstract T
9 Assessment of Top-Down Versus Step-Up Strategies in CD Newly diagnosed CD of < 4 CDAI < 15 Points years duration (N = 129) AND No Steroids Naive to immunomodulators AND No Surgery 1 and biologics IFX + AZA + (episodic) IFX Top-down (n = 65) Steroids IFX (Wk, 2, 6) + AZA +IFX +AZA MTX Steroids Step-up (n = 64) Steroids Steroids Hommes D, et al. DDW 26, Abstract Co-primary endpoints 6 & 12 months Weeks Top-down Step-up P <.1; P <.5 Top-Down Versus Step-Up Trial Clinical Results at 2 Years Reduction and Disappearance of Ulcers Top-down 1 p <.1 Step-up 88 5 p < Patients Receiving Immunosuppressants Reduction Disappearance Weeks Hommes D, et al. DDW 26, Abstract 749.; D Haens GR, et al. DDW 26. Abstract Top-down Step-up Patients Receiving Infliximab Continuation of Immunomodulators (IMMs) Is Not Required to Maintain Efficacy With Biologic Agents Infliximab Adalimumab (CLASSIC II) Natalizumab (ENACT-2) With concomitant IMMs Without concomitant IMMs n = n = n = Success CDAI CDAI CDAI CDAI (No CDAI 7) 1 <15 7 <15 mg EOW or weekly. van Assche G, et al. Panaccione, et al. Sandborn, et al. DDW 26, Abstract 923. DDW 26, Abstract T1124. DDW 26, Abstract T Crohn s s Disease: The Future Anti-TNF: 3 FDA approved agents likely in 27 What will guide choice? Patient convenience, cost, immunogenicity? Top down therapy Patient selection Natalizumab Safety monitoring plan Anti-IL-12/23 CTLA4 Ig (abatacept) Sargramostim Pheresis Other targets 9
10 MMX mesalamine (SPD476): induction of remission in patients with mild and moderate UC Ulcerative Colitis MMX = Multi Matrix System TM mesalamine, a novel once-daily, high-strength formulation of 5-ASA (mesalamine 1.2 g tablet) designed to release 5-ASA throughout the colon Mild-to-moderate UC (score of 4 1 on UC-DAI) with: Sigmoidoscopy score 1 PGA score 2 Relapse 6 weeks prior to baseline MMX mesalamine 2.4 g/day Randomization MMX mesalamine 4.8 g/day give QD 8-week treatment period Primary endpoint: remission after 8 weeks treatment Remission = UC-DAI 1 with score of for rectal bleeding and stool frequency, and 1-point reduction from baseline in sigmoidoscopy score NB: Study SPD476-2 also included a reference arm (Asacol [US formulation, Procter & Gamble Pharmaceuticals, Cincinnati, OH, USA] 2.4 g/day given in three divided doses) MMX mesalamine2.4 g/day was give in two divided doses in study SPD476-31, and once daily in SPD UC = ulcerative colitis; UC-DAI ulcerative colitis-disease activity index; PGA = Physician s Global Assessment; QD = once daily 1. Sandborn WJ, et al. DDW 26, #T1139; 2. Lichtenstein GR, et al. ibid, #T1147; 3. Kamm MA, et al. ibid, #T1148; 4. Sandborn, WJ et al. ibid, #813 MMX mesalamine (SPD476) in mild-to-moderate UC: subgroup analyses (remission rates) MMX mesalamine 2.4 g/d MMX mesalamine 4.8 g/d Mild Moderate Left-sided Extensive ASA naïve Failing 2 gm/d 5-ASA p<.1 vs placebo p.1 vs placebo p<.1 vs placebo p<.5 post-hoc analysis Curcumin for long-term maintenance therapy in patients with UC Background Pharmacologically active phytochemical derived from turmeric Suppresses NF-kB Study design Multicenter, double-blinded, placebo-controlled trial Patients with quiescent UC (CAI 4 for 4 weeks) randomized to curcumin 2g/day (n=45) or placebo (n=44) Continued on sulfasalazine or 5-ASA Primary analysis: Relapse rates by 6 months 1. Sandborn WJ, et al. DDW 26, #T1139; 2. Lichtenstein GR, et al. ibid, #T1147; 3. Kamm MA, et al. ibid, #T1148; 4. Sandborn WJ, et al. ibid, #813 Hanai H, et al. DDW 26, #572 1
11 Curcumin for long-term maintenance therapy in patients with UC Ulcerative Colitis: The Future Patients in remission (%) cases relapsed Curcumin 2 cases relapsed 4.6% 2.5% 3 months 6 months p<.49 Where will infliximab be positioned? Moderate, steroid refractory outpatients. Efficacy in severe disease? Other TNF inhibitors Visilizumab (anti-cd3) Severe IV steroid refractory inpatients? Retreatment, safety, immunogenicity, durability? MLN-2 (anti-α4β7) CTLA4 Ig (abatacept) Pheresis Other targets Hanai H, et al. DDW 26, #572 Conclusions There is substantial unmet need for therapy of IBD New biologic agents and a host of other pipeline therapies are being developed for CD Need to understand which ones to use and when to use them Need to communicate safety issues effectively to our colleagues and patients Need long-term outcome data! New aminosalicylate may offer convenient on-label dosing in UC, but is likely not superior to other therapies Need to understand who and how to use New patients? All patients? Cost and access to care will be an issue for all new therapies It s time we faced reality, my friends.. There s plenty of room for improvement. 11
Biologic Therapy for Inflammatory. Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida
Biologic Therapy for Inflammatory Bowel Disease: Is Top-Down Too Top-Heavy? S. Devi Rampertab, MD, FACG, AGAF Associate Professor of Medicine University of Florida Learning Objectives Evaluate evidence
More informationSevere IBD: What to Do When Anti- TNFs Don t Work?
Severe IBD: What to Do When Anti- TNFs Don t Work? David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and
More informationAn Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease. David A. Schwartz, MD
An Update on the Biologic Treatment for Patients with Inflammatory Bowel Disease David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University
More informationPosition of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy
Position of Biologics in IBD Circa 2006: Top Down vs. Step Up Therapy Stephen B. Hanauer, MD University of Chicago Potential Conflicts: Centocor/Schering, Abbott, UCB, Elan, Berlex, PDL Goals of Treatment
More informationHow to Optimize Induction and Maintenance Responses: Definitions and Dosing Advances in Inflammatory Bowel Disease December 6, 2009
How to Optimize Induction and Maintenance Responses: Definitions and Dosing 2009 Advances in Inflammatory Bowel Disease December 6, 2009 Fernando Velayos MD MPH University of California, San Francisco
More informationIndications for use of Infliximab
Indications for use of Infliximab Moscow, June 10 th 2006 Prof. Dr. Dr. Gerhard Rogler Klinik und Poliklinik für Innere Medizin I Universität Regensburg Case report 1989: Diagnosis of Crohn s disease of
More informationHow do I choose amongst medicines for inflammatory bowel disease. Maria T. Abreu, MD
How do I choose amongst medicines for inflammatory bowel disease Maria T. Abreu, MD Overview of IBD Pathogenesis Bacterial Products Moderately Acutely Inflamed Chronic Inflammation = IBD Normal Gut Mildly
More informationEmerging g therapies for IBD: A practical approach to positioning. Sequential Therapies for IBD
Emerging g therapies for IBD: A practical approach to positioning Stephen B. Hanauer, MD Sequential Therapies for IBD Disease Severity at Presentation Severe Anti-TNF +/IS Cyclosporine (UC) Colectomy (UC)
More informationTherapy for Inflammatory Bowel Disease
Therapy for Inflammatory Bowel Disease Jonathan P. Terdiman, MD Professor of Clinical Medicine Clinical Director, Center for Colitis and Crohn s Disease University of California San Francisco, CA UC: Current
More informationUpdate on Biologics in Ulcerative Colitis. Scott Plevy, MD University of North Carolina Chapel Hill, NC
Update on Biologics in Ulcerative Colitis Scott Plevy, MD University of North Carolina Chapel Hill, NC Objectives Discuss the latest advances in the pharmacologic management of ulcerative colitis Describe
More informationIBD Updates. Themes in IBD IBD management journey. New tools for therapeutic monitoring. First-line treatment in IBD
IBD Updates Maria T. Abreu, MD University of Miami Miller School of Medicine Miami, Florida Themes in IBD 213 First-line treatment in IBD New tools for therapeutic monitoring Biologic therapy for CD and
More informationAzathioprine for Induction and Maintenance of Remission in Crohn s Disease
Azathioprine for Induction and Maintenance of Remission in Crohn s Disease William J. Sandborn, MD Chief, Division of Gastroenterology Director, UCSD IBD Center Objectives Azathioprine as induction and
More informationVedolizumab: policing leukocyte traffic
Oxford Inflammatory Bowel Disease MasterClass Vedolizumab: policing leukocyte traffic Dr Brian Feagan, London, Canada Vedolizumab : Policing Lymphocyte Traficking Brian G. Feagan Professor of Medicine,
More informationBiologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases
Biologics, Novel Therapeutic Approaches in Inflammatory Bowel Diseases Walter Reinisch Univ-Klinik für Innere Medizin III Abt. Gastroenterologie & Hepatologie AKH Wien The Biologic s evolution From availabilitydriven
More informationRecent Advances in the Management of Refractory IBD
Recent Advances in the Management of Refractory IBD Raina Shivashankar, M.D. Assistant Professor of Medicine Division of Gastroenterology and Hepatology Thomas Jefferson University Philadelphia, PA Outline
More informationAli Keshavarzian MD Rush University Medical Center
Treatment: Step Up or Top Down? Ali Keshavarzian MD Rush University Medical Center Questions What medication should IBD be treated with? Can we predict which patients with IBD are high risk? Is starting
More informationSeptember 12, 2015 Millie D. Long MD, MPH, FACG
Update on Biologic Therapy in 2015 September 12, 2015 Millie D. Long MD, MPH, FACG Assistant Professor of Medicine Inflammatory Bowel Disease Center University of North Carolina-Chapel Hill Outline Crohn
More informationNew treatment options in UC. Rob Bryant IBD Consultant Royal Adelaide Hospital
New treatment options in UC Rob Bryant IBD Consultant Royal Adelaide Hospital Talk Outline 1. Raising expectations 2. Optimising UC therapy 3. Clinical trials 4. What s new on the PBS? 5. Questions 1.
More informationPositioning New Therapies
Positioning New Therapies Stephen Hanauer, MD Professor of Medicine Medical Director, Digestive Disease Center Northwestern Medicine Chicago, Illinois Speaker Disclosure Stephen Hanauer, MD has disclosed
More informationNew and Future Adhesion Molecule Based Therapies in IBD
New and Future Adhesion Molecule Based Therapies in IBD Brian G. Feagan Professor of Medicine, Epidemiology and Biostatistics University of Western Ontario Robarts Clinical Trials London, Ontario, Canada
More informationTumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review)
Tumor necrosis factor-alpha antibody for maintenace of remission in Crohn s disease (Review) Behm BW, Bickston SJ This is a reprint of a Cochrane review, prepared and maintained by The Cochrane Collaboration
More informationMono or Combination Therapy with. Individualized Approach
Mono Combination Therapy with Biologics i in IBD: Developing an Individualized Approach David T. Rubin, MD, FACG Co-Direct, Inflammaty Bowel Disease Center Fellowship Program Direct University of Chicago
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Associate Professor of Clinical Pediatrics Division of Gastroenterology,
More informationTreatment Goals. Current Therapeutic Pyramids Crohn s Disease Ulcerative Colitis 11/14/10
Current Management of IBD: From Conventional Agents to Biologics Stephen B. Hanauer, M.D. University of Chicago Treatment Goals Induce and maintain response/ remission Prevent complications Improve quality
More informationBiologic Therapy for Ulcerative Colitis in 2015
5/6/215 Biologic Therapy for Ulcerative Colitis in 215 John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University Bressler B, Marshall JK, et al. Gastroenterology 215;148: 135-58
More informationEfficacy and Safety of Treatment for Pediatric IBD
Efficacy and Safety of Treatment for Pediatric IBD Andrew B. Grossman MD Co-Director, Center for Pediatric Inflammatory Bowel Disease Assistant Professor of Clinical Pediatrics Division of Gastroenterology,
More informationMedical Therapy for Pediatric IBD: Efficacy and Safety
Medical Therapy for Pediatric IBD: Efficacy and Safety Betsy Maxwell, MD Assistant Professor of Clinical Pediatrics Division of Gastroenterology, Hepatology, and Nutrition Pediatric IBD: Defining Remission
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: Feb. 14, 2018 Last Revised: April 1, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationBiologics in IBD. Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College
Biologics in IBD Brian P. Bosworth, MD, NYSGEF Associate Professor of Medicine Weill Cornell Medical College Case 30 year old man diagnosed with ulcerative proctitis diagnosed in 2003 Had been maintained
More informationThe following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only.
The following slides are provided as presented by the author during the live educa7onal ac7vity and are intended for reference purposes only. If you have any ques7ons, please contact Imedex via email at:
More informationImmunogenicity of Biologic Agents and How to Prevent Sensitization
Immunogenicity of Biologic Agents and How to Prevent Sensitization William J. Sandborn, MD Professor and Chief, Division of Gastroenterology Director, UCSD IBD Center La Jolla, California, USA Learning
More informationNew treatment options in IBD: today and the future. Silvio Danese Istituto Clinico Humanitas, Milan, Italy
New treatment options in IBD: today and the future Silvio Danese Istituto Clinico Humanitas, Milan, Italy Date of preparation: October 2014 GLO/EYV/2014-00010h Overview of the late-stage IBD drug pipeline*
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: June 9, 2019* Last Revised: Feb. 12, 2019 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationInitiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease
Initiation of Maintenance Treatment in Moderate to Severe New Onset Crohn s Disease The Case for Starting with Anti-TNFα Agents Maria Oliva-Hemker, M.D. Chief, Division of Pediatric Gastroenterology &
More informationGionata Fiorino VEDOLIZUMAB E IBD. Un nuovo target terapeutico
Gionata Fiorino VEDOLIZUMAB E IBD Un nuovo target terapeutico Anti cell adhesion molecules Danese S, NEJM 2011 6 Steps leukocyte recruitment Fiorino G. et al. 2010 Vedolizumab Blocks Fewer Biological Pathways
More informationModerately to severely active ulcerative colitis
Adalimumab in the Treatment of Moderate-to-Severe Ulcerative Colitis: ULTRA 2 Trial Results Sandborn WJ, van Assche G, Reinisch W, et al. Adalimumab induces and maintains clinical remission in patients
More informationCROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM
CROHN'S DISEASE/ULCERATIVE COLITIS TREATMENT ALGORITHM Crohn's Disease Ulcerative Colitis Steroids x 2 No prior AZA/6-MP Biologic Agent AZA/6-MP STEP-UP MANAGEMENT APPROACH Advantages Patients attain remission
More informationPharmacy Management Drug Policy
SUBJECT: Multiple Sclerosis, Crohn s Disease POLICY NUMBER: PHARMACY-53 EFFECTIVE DATE: 4/08 LAST REVIEW DATE: 12/18/2018 If the member s subscriber contract excludes coverage for a specific service or
More informationMedical Management of Inflammatory Bowel Disease
Medical Management of Inflammatory Bowel Disease John K. Marshall MD MSc FRCPC AGAF Division of Gastroenterology McMaster University John K. Marshall: Conflicts of Interest Speaker: AbbVie, Allergan, Ferring,
More informationSelby Inflamm Bowel Dis. 2008:14:
Medical Management of Inflammatory Bowel Disease Freddy Caldera D.O. Assistant Professor Division of Gastroenterology Objectives Discuss Crohn s disease and Ulcerative Colitis Discuss Medications for Inflammatory
More informationMucosal Healing in Crohn s Disease. Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium
Mucosal Healing in Crohn s Disease Geert D Haens MD, PhD University Hospital Gasthuisberg University of Leuven Leuven, Belgium Mucosal Lesions in CD: General Features CD can affect the entire GI tract
More informationLatest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D.
Latest Treatment Updates for Crohn s Disease: Tailoring Therapy David G. Binion, M.D. Co-Director, IBD Center Director, Nutrition Support Service UPMC Presbyterian Hospital Division of Gastroenterology,
More informationPharmacotherapy of Inflammatory Bowel Disorder
PHARMACY / MEDICAL POLICY 5.01.563 Pharmacotherapy of Inflammatory Bowel Disorder Effective Date: May 1, 2018 Last Revised: April 18, 2018 Replaces: Extracted from 5.01.550 RELATED MEDICAL POLICIES: 11.01.523
More informationHow to use infliximab?
How to use infliximab? Séverine Vermeire, MD, PhD Division of Gastroenterology University Hospital Gasthuisberg Leuven The how to use infliximab rules Before starting IFX: try optimizing chances for response!
More informationPerianal and Fistulizing Crohn s Disease: Tough Management Decisions. Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic
Perianal and Fistulizing Crohn s Disease: Tough Management Decisions Jean-Paul Achkar, M.D. Kenneth Rainin Chair for IBD Research Cleveland Clinic Talk Overview Background Assessment and Classification
More informationBiologic therapies for inflammatory bowel disease (IBD)
GASTROENTEROLOGY 2007;133:312 339 American Gastroenterological Association Consensus Development Conference on the Use of Biologics in the Treatment of Inflammatory Bowel Disease, June 21 23, 2006 The
More informationBeyond Anti TNFs: positioning of other biologics for Crohn s disease. Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center
Beyond Anti TNFs: positioning of other biologics for Crohn s disease Christina Ha, MD Cedars Sinai Inflammatory Bowel Disease Center Objectives: To define high and low risk patient and disease features
More informationUlcerative colitis (UC) is a chronic inflammatory
Induction and Maintenance Therapy with Vedolizumab, a Novel Biologic Therapy for Ulcerative Colitis Feagan BG, Rutgeerts P, Sands BE, et al; GEMINI 1 Study Group. Vedolizumab as induction and maintenance
More informationAchieving Success in Ulcerative Colitis: the Role of Infliximab
Achieving Success in Ulcerative Colitis: the Role of Infliximab Dr Gill Watermeyer IBD clinic Groote Schuur Hospital 17 th August 2012 Inflammatory Bowel Disease Crohn s disease and ulcerative colitis
More informationSubmitted by xxxxxxxxxxxxxxxxx, xxxxxxxxx RCP and co-ordinated by xxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxxxxxx, Royal Liverpool University Hospital.
Royal College of Physicians statement on the appraisal of use of tumour necrosis factor alpha (TNF-α) inhibitors (adalimumab, certolizumab pegol and infliximab) and natalizumab for Crohn's disease Submitted
More informationCCFA. Crohns Disease vs UC: What is the best treatment for me? November
CCFA Crohns Disease vs UC: What is the best treatment for me? November 8 2009 Ellen J. Scherl,, MD, FACP,AGAF Roberts Inflammatory Bowel Disease Center Weill Medical College Cornell University New York
More informationOptimizing the effectiveness of anti-tnf therapy in paediatric IBD
Optimizing the effectiveness of anti-tnf therapy in paediatric IBD Anne Griffiths MD, FRCPC Co-Lead, Inflammatory Bowel Disease Center Northbridge Chair in IBD Hospital for Sick Children, Professor of
More informationU of Cape Town, South Africa, 10 U of Washington, Seattle, WA,USA, 11 CHRU de Lille, Hôpital Claude Huriez, Lille, France, 12
A Multicenter, Double-blind, Placebo-controlled Phase 3 Study of Ustekinumab, a Human IL-12/23p40 Monoclonal Antibody, in Moderate-severe Crohn s Disease Refractory to Anti-TNFα: UNITI-1 WJ Sandborn 1,
More informationAssociation Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease
Association Between Plasma Concentrations of Certolizumab Pegol and Endoscopic Outcomes of Patients With Crohn's Disease Jean Frédéric Colombel, William J. Sandborn, Matthieu Allez, Jean Louis Dupas, Olivier
More informationPositioning Biologics in Ulcerative Colitis
Positioning Biologics in Ulcerative Colitis Bruce E. Sands, MD, MS Acting Chief, Gastrointestinal Unit Massachusetts General Hospital Associate Professor of Medicine Harvard Medical School Sequential Therapies
More informationAnne Griffiths MD, FRCPC. SickKids Hospital, University of Toronto. Buenos Aires, August 16, 2014
Management and Medical Therapies for Crohn disease: strategies to enhance mucosal healing Anne Griffiths MD, FRCPC SickKids Hospital, University of Toronto Buenos Aires, August 16, 2014 New onset Crohn
More informationPersonalized Medicine in IBD: Where Are We in 2013
Personalized Medicine in IBD: Where Are We in 2013 David A. Schwartz, MD Director, Inflammatory Bowel Disease Center Associate Professor of Medicine Vanderbilt University Medical Center What is Personalized
More informationTreating to Achieve a Target and Disease Monitoring in 2015: State of the Art
Treating to Achieve a Target and Disease Monitoring in 2015: State of the Art David T. Rubin, MD The Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationENTYVIO (VEDOLIZUMAB)
ENTYVIO (VEDOLIZUMAB) UnitedHealthcare Community Plan Medical Benefit Drug Policy Policy Number: CS2017D0053F Effective Date: July 1, 2017 Table of Contents Page INSTRUCTIONS FOR USE... 1 BENEFIT CONSIDERATIONS...
More informationDisclosures. What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists
What Do I Do When Anti-TNF Therapy Is Not Working Anymore? Fadi Hamid, M.D. Saint Luke s GI Specialists Disclosures No financial relationships to disclose. 1 Learning Objectives Case 24M with ileocolonic
More informationAgenda. Predictive markers in IBD. Management of ulcerative colitis. Management of Crohn s disease
Agenda Predictive markers in IBD Management of ulcerative colitis Management of Crohn s disease 2 Patients With UC (%) Distribution of UC Disease Severity at Presentation 1 Fulminant disease (9%) 8 6 4
More informationThe Best of IBD at UEGW (Crohn s)
The Best of IBD at UEGW (Crohn s) Iyad Issa MD Head of Gastroenterology, Rafik Hariri Univ Hosp Adjunct Faculty, School of Medicine, Leb Univ Founding Faculty, School Of Medicine, Leb Am Univ 1 The Best
More informationCommon Questions in Crohn s Disease Therapy. Case
Common Questions in Crohn s Disease Therapy Jean-Paul Achkar, MD, FACG Kenneth Rainin Chair for IBD Research Cleveland Clinic Case 23 yo male with 1 year history of diarrhea, abdominal pain and 15 pound
More information1. Comparative effectiveness of vedolizumab
Cost-effectiveness of vedolizumab (Entyvio ) for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response with, lost response to, or were
More informationPredicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab.
Predicting response to anti - integrin therapy: long term efficacy and roles for optimisation with vedolizumab. Dr Peter Irving Guy s and St Thomas Hospital, London King s College London Response to vedolizumab
More informationBiologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA
Biologics in 2016: How Do We Select the Most Appropriate Agent? Gary R. Lichtenstein, MD, FACG University of PA School of Medicine Philadelphia, PA Overview Indications and Drug Selection Contraindications
More information2.0 Synopsis. Adalimumab M Clinical Study Report Final R&D/15/1054. (For National Authority Use Only)
2.0 Synopsis AbbVie Inc. Name of Study Drug: Adalimumab Name of Active Ingredient: Adalimumab Individual Study Table Referring to Part of Dossier: Volume: Page: (For National Authority Use Only) Title
More informationEndpoints for Stopping Treatment in UC
Endpoints for Stopping Treatment in UC Jana G. Hashash, MD Assistant Professor of Medicine Inflammatory Bowel Disease Center Division of Gastroenterology, Hepatology, and Nutrition University of Pittsburgh
More informationSelection and use of the non-anti- TNF biological therapies: Who? When? How?
Selection and use of the non-anti- TNF biological therapies: Who? When? How? Asher Kornbluth, MD Clinical Professor of Medicine The Henry D. Janowitz Division of Gastroenterology The Icahn School of Medicine
More informationSYNOPSIS. Issue Date: 25 Oct 2011
SYNOPSIS Issue Date: 25 Oct 2011 Name of Sponsor/Company Name of Finished Product Name of Active Ingredient(s) Janssen Research & Development STELARA Ustekinumab Protocol No.: Title of Study: Study Name:
More informationChoosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball
Choosing and Positioning Biologic Therapy for Crohn s Disease: (Still) Looking for the Crystal Ball Siddharth Singh, MD, MS Assistant Professor of Medicine Division of Gastroenterology Division of Biomedical
More informationPractical Risk Management Tools for Patients with IBD. Garth Swanson MD Rush University Medical Center
Practical Risk Management Tools for Patients with IBD Garth Swanson MD Rush University Medical Center IBD Therapy Severity Tysabri Surgery Infliximab, i Adalimumab, Certilizumab Corticosteroids, Immunomodulators
More informationFuture Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018
Future Directions in IBD: Treatments & Approaches JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER APRIL 29, 2018 Why do pharmaceuticals dominate IBD therapy discussions?
More informationOptimizing Therapies for Severe Ulcerative Colitis October 19, 2014
Optimizing Therapies for Severe Ulcerative Colitis October 19, 2014 Ellen J. Scherl, MD, FACP, FACG, AGAF, FASGE, NYSGEF Director Jill Roberts Center for Inflammatory Bowel Disease Jill Roberts IBD Research
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 October 2010 MEZAVANT LP 1200 mg, prolonged-release gastro-resistant tablets B/60 (CIP code: 378 689-2) Applicant
More informationIBD Understanding Your Medications. Thomas V. Aguirre, MD Santa Barbara GI Consultants
IBD Understanding Your Medications Thomas V. Aguirre, MD Santa Barbara GI Consultants IBD Understanding Your Medications (& Your Doctor) Thomas V. Aguirre, MD Santa Barbara GI Consultants Disclosure I
More informationFuture Therapies in IBD. William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota
Future Therapies in IBD William J. Sandborn, M.D. Mayo Clinic, Rochester, Minnesota Korzenik et al. Nature Reviews Drug Discovery 5, 197 209 (March 2006) doi:10.1038/nrd1986 Therapies for IBD: The Pipeline
More informationOptimal Use of Immunomodulators and Biologics
3/17/214 Optimal Use of Immunomodulators and Biologics Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology and Hepatology Mayo Clinic Rochester, Minnesota, U.S.A. Loftus Disclosures
More informationOf Treatment For Inflammatory Bowel Diseases
Balancing The Risks And Benefits Of Treatment For Inflammatory Bowel Diseases Corey A. Siegel, MD Assistant Professor of Medicine Dartmouth Medical School Director, Inflammatory Bowel Diseases Center Dartmouth-Hitchcock
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 4,100 116,000 120M Open access books available International authors and editors Downloads Our
More informationLatest Meds Approved for IBD: What are they and how do they work?
Latest Meds Approved for IBD: What are they and how do they work? JAMES LORD, MD PHD BENAROYA RESEARCH INSTITUTE AT VIRGINIA MASON MEDICAL CENTER SEPT 30, 2018 Brief history of IBD Dr. Burrill Crohn JAMA
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationThe Refractory Crohn s Disease
The Refractory Crohn s Disease Patient David T. Rubin, MD, FACG Professor of Medicine Co-Director, Inflammatory Bowel Disease Center Interim Chief, Section of Gastroenterology, Hepatology and Nutrition
More informationIBD Biologicals and Novel therapeutic regimes. Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh
IBD Biologicals and Novel therapeutic regimes Dr S K Sinha Additional Professor Department of Gastroenterology PGIMER, Chandigarh 1 Treatment aims in IBD Traditional treatment goals of IBD Control of symptoms?improvement
More informationΑπό τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών. Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων
Από τη θεωρία στη πράξη: Συζήτηση κλινικών περιστατικών Κωνσταντίνος Κατσάνος Επίκουρος Καθηγητής Γαστρεντερολογίας Πανεπιστήμιο Ιωαννίνων Conflict of interest By means of this, the speaker confirms that
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Brian Feagan, MD, FACG Professor of Medicine and Epidemiology and Biostatistics Director, Robarts Clinical Trials Robarts Research Institute University
More informationPersonalized Medicine. Selecting the Right First-line Biologic Agent. Gene Expression Profiles Crohn s Disease. The Right Treatment
Personalized Medicine Selecting the Right First-line Biologic Agent William Tremaine, M.D. Maxine and Jack Zarrow Professor Mayo Clinic Rochester, MN, USA The Right Treatment Pretreatment Genomic Analysis
More informationManagement of Refractory Crohn s Disease
Management of Refractory Crohn s Disease @IBDMD David T. Rubin, MD, FACG, FASGE Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Disclosures Consultant
More informationCrohn's Disease. The What, When, and Why of Treatment
Crohn's Disease The What, When, and Why of Treatment Gary R. Lichtenstein, MD, FACG Professor of Medicine Director, Inflammatory Bowel Disease Program University of Pennsylvania Philadelphia, PA In my
More informationInflammatory bowel disease (IBD) Overview of the Paediatric investigation plans. Presented by: Richard Veselý. An agency of the European Union
Inflammatory bowel disease (IBD) Overview of the Paediatric investigation plans Presented by: Richard Veselý An agency of the European Union Adalimumab - Crohn s disease Indication: Treatment of severe,
More informationInflammatory Bowel Disease Drug Therapy 2016
Inflammatory Bowel Disease Drug Therapy 206 David T. Rubin, MD, FACG Joseph B. Kirsner Professor of Medicine Chief, Section of Gastroenterology, Hepatology and Nutrition Objectives Outline the goals of
More information5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease
5-ASA Therapy, Steroids and Antibiotics in Inflammatory Bowel Disease David T. Rubin, MD Associate Professor of Medicine Co-Director, Inflammatory Bowel Disease Center University it of Chicago Medical
More informationGenetics. Environment. You Are Only 10% Human. Pathogenesis of IBD. Advances in the Pathogenesis of IBD: Genetics Leads to Function IBD
Advances in the Pathogenesis of IBD: Genetics Leads to Function Pathogenesis of IBD Environmental Factors Microbes Scott Plevy, MD Associate Professor of Medicine, Microbiology & Immunology UNC School
More informationUlcerative Colitis Therapy. Faculty Disclosure. Acknowledgements 28/11/2013. Amy Morse November 30/13
Ulcerative Colitis Therapy Amy Morse November 30/13 GI for GP s Jasper AB Faculty Disclosure Faculty: Amy Morse Relationships with commercial interests: Grants/Research Support: Therapeutic Fellowship
More informationTherapies for IBD: the Pipeline. New Therapeutic Agents in IBD
Therapies for IBD: the Pipeline New Therapeutic Agents in IBD William J. Sandborn, MD Professor & Chief, Division of Gastroenterology Director, UCSD IBD Center Budesonide Oral MMX budesonide Rectal budesonide
More informationTo help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture,
To help protect your privacy, PowerPoint prevented this external picture from being automatically downloaded. To download and display this picture, click Options in the Message Bar, and then click Enable
More informationTitle: Author: Journal:
IMPORTANT COPYRIGHT NOTICE: This electronic article is provided to you by courtesy of Ferring Pharmaceuticals. The document is provided for personal usage only. Further reproduction and/or distribution
More informationAre Biologicals Safe Enough?
Are Biologicals Safe Enough? Dr Anne Duggan Director of Gastroenterology, John Hunter Hospital, Hunter New England Area Health Service (HNEAHS) Conjoint A/Professor, University of Newcastle, Australia
More informationFistulizing Crohn s Disease: The Aggressive Approach
Fistulizing Crohn s Disease: The Aggressive Approach Bruce E. Sands, MD, MS MGH Crohn s and Colitis Center and Gastrointestinal Unit Massachusetts General Hospital Boston, USA Case Presentation: Summary
More informationPercent Cumulative. Probability. Penetrating. Inflammatory. Stricturing. Months Patients at risk N =
Fistulizing Crohn s Disease Edward V. Loftus, Jr., M.D. Professor of Medicine Division of Gastroenterology & Hepatology Mayo Clinic Rochester, Minnesota, USA Outline Fistulizing Crohn s Etiology Incidence
More information